Efalizumab
From Wikipedia, the free encyclopedia
|
Efalizumab?
|
|
| Therapeutic monoclonal antibody | |
| Source | Human |
| Target | CD11a |
| Identifiers | |
| CAS number | |
| ATC code | L04 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Efalizumab (Raptiva, Genentech) is a medication used to treat psoriasis. It is a recombinant humanized monoclonal antibody that binds to CD11a and acts as an immunosuppressant. It is administered once weekly by subcutaneous injection.
It acts to inhibit white blood cell migration out of blood vessels into tissues.
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||
